ESPR Stock Overview
A pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Esperion Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.69 |
| 52 Week High | US$3.94 |
| 52 Week Low | US$1.47 |
| Beta | 1.04 |
| 1 Month Change | -7.14% |
| 3 Month Change | -24.55% |
| 1 Year Change | -26.20% |
| 3 Year Change | -65.51% |
| 5 Year Change | -95.21% |
| Change since IPO | -88.34% |
Recent News & Updates
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Feb 22Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Dec 08Recent updates
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Feb 22Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Dec 08Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
Nov 13Esperion Therapeutics: Strategically Positioned To Grow
Aug 16Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24Shareholder Returns
| ESPR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.7% | 1.7% | 0.6% |
| 1Y | -26.2% | 1.1% | 7.9% |
Return vs Industry: ESPR underperformed the US Pharmaceuticals industry which returned 1.1% over the past year.
Return vs Market: ESPR underperformed the US Market which returned 7.9% over the past year.
Price Volatility
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 8.2% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ESPR has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ESPR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 304 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company’s marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C.
Esperion Therapeutics, Inc. Fundamentals Summary
| ESPR fundamental statistics | |
|---|---|
| Market cap | US$334.36m |
| Earnings (TTM) | -US$51.74m |
| Revenue (TTM) | US$332.31m |
1.0x
P/S Ratio-6.5x
P/E RatioIs ESPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ESPR income statement (TTM) | |
|---|---|
| Revenue | US$332.31m |
| Cost of Revenue | US$114.84m |
| Gross Profit | US$217.48m |
| Other Expenses | US$269.22m |
| Earnings | -US$51.74m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.26 |
| Gross Margin | 65.44% |
| Net Profit Margin | -15.57% |
| Debt/Equity Ratio | -150.7% |
How did ESPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 22:09 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Esperion Therapeutics, Inc. is covered by 18 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |